Shopping Cart 0
Cart Subtotal
AED 0

Physician Perspectives 2017: Biosimilar use in IBD

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 27525

Details

Physician Perspectives 2017: Biosimilar use in IBD

Summary

This Physician Perspectives survey focuses on the use of biosimilar anti-TNFs in IBD.

In the next 12 months, nearly half of physicians stated that they would consider switching Remicade patients (in remission) over to biosimilar IFX. A large proportion of physicians reported that their patients have at least occasionally expressed concern (rated >3) over being switched onto a biosimilar anti-TNF from an originator anti-TNF (67%) or being prescribed a biosimilar anti-TNF (54%). Overall, the majority of physicians agreed that they would require a biosimilar to be designated as interchangeable before considering switching patients from an originator to a biosimilar (67%).

The report includes following topics-

- Familiarity with biosimilar IFX

- Expected use of biosimilars-IFX & ADA

- Concerns with biosimilars

- Switching & Interchangeability.

Scope

- Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists

- Physicians interviewed were from 5EU and US countries This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.

Reasons to buy

- Qualitative insight from 100 high-prescribing specialists in IBD

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of contents

Executive Summary

Methodology

Survey Results

Demographics

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Biosimilars, IBD, interchangeability


Companies

Janssen

Celltrion

AbbVie

Company Profile

Company Profile Title

Physician Perspectives 2017: Biosimilar use in IBD

Summary

This Physician Perspectives survey focuses on the use of biosimilar anti-TNFs in IBD.

In the next 12 months, nearly half of physicians stated that they would consider switching Remicade patients (in remission) over to biosimilar IFX. A large proportion of physicians reported that their patients have at least occasionally expressed concern (rated >3) over being switched onto a biosimilar anti-TNF from an originator anti-TNF (67%) or being prescribed a biosimilar anti-TNF (54%). Overall, the majority of physicians agreed that they would require a biosimilar to be designated as interchangeable before considering switching patients from an originator to a biosimilar (67%).

The report includes following topics-

- Familiarity with biosimilar IFX

- Expected use of biosimilars-IFX & ADA

- Concerns with biosimilars

- Switching & Interchangeability.

Scope

- Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists

- Physicians interviewed were from 5EU and US countries This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.

Reasons to buy

- Qualitative insight from 100 high-prescribing specialists in IBD

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of contents

Executive Summary

Methodology

Survey Results

Demographics

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Biosimilars, IBD, interchangeability


Companies

Janssen

Celltrion

AbbVie